Jagsonpal to acquire Group Pharma’s Wellness Portfolio for up to ₹46.7 crore

We are pleased with our FY25 performance, which underscores the strength of our strategy and execution.

Aequitas alone, we are looking at around Rs.100 crores of business within two and a half years' time, starting from now.

Starting with a revenue base of Rs.53 crores, we are targeting Rs.10 crores EBITDA by year two post-integration, driving higher revenue contribution and improving profitability from FY27.

Aequitas alone, we are looking at around Rs.100 crores of business within two and a half years' time, starting from now.

And I think we have given that in the board deck as well. And we are certainly targeting upward of Rs.10 crores of EBITDA.

As our M.D. sir said, we will grow revenue and that growth must translate into stronger profits.